NCT05192642View on ClinicalTrials.gov

A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice

CompletedOBSERVATIONAL
Enrollment

368

Participants

Timeline

Start Date

December 3, 2021

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2023

Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
DRUG

Larotrectinib(Vitrakvi, BAY2757556)

Clinical trials

DRUG

Data on other treatments

Real word data

Trial Locations (1)

07981

Bayer, Whippany

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT05192642 - A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice | Biotech Hunter | Biotech Hunter